CELESTE BROERMAN: Open Payments
NPI 1932127388 · SAN ANTONIO, TX. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$453 in 20 payments from 10 companies in 2025. Trend: 2023 $220 · 2024 $264 · 2025 $453
Food & beverage: $453
| Company | Payments | Amount |
|---|---|---|
| Dexcom, Inc. | 5 | $180 |
| Sumitomo Pharma America, Inc. | 3 | $52 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 2 | $43 |
| Novo Nordisk Inc | 2 | $43 |
| Abbott Laboratories | 2 | $38 |
| VERTEX PHARMACEUTICALS INCORPORATED | 1 | $30 |
| GlaxoSmithKline, LLC. | 1 | $21 |
| Seqirus USA Inc | 1 | $20 |
| Merck Sharp & Dohme LLC | 1 | $18 |
| Dynavax Technologies Corporation | 2 | $9 |
Products named: Dexcom G6 Transmitter, GEMTESA, JARDIANCE, FREESTYLE LIBRE 3, JOURNAVX, TRELEGY ELLIPTA, Fluad, CAPVAXIVE.
Industry payments across TX — which companies pay providers there.
